What Is Continuous Glucose Monitoring?

Continuous Glucose Monitoring (CGM) is a technology that tracks glucose levels in real time throughout the day and night. Unlike traditional fingerstick testing, which provides a single snapshot of blood glucose at a moment in time, a CGM system delivers a continuous stream of data, allowing people with diabetes to see how their glucose responds to meals, exercise, medication, and other lifestyle factors. This ongoing feedback loop enables more precise insulin dosing, fewer episodes of severe hypoglycemia, and greater confidence in daily diabetes management.

CGM systems have evolved rapidly over the past decade. Early devices were bulky, required frequent calibration, and had limited connectivity. Today’s systems are smaller, more accurate, and integrate seamlessly with smartphones, smartwatches, and insulin pumps. The technology is now considered the standard of care for many people with type 1 diabetes and is increasingly adopted for type 2 diabetes, particularly for those on intensive insulin therapy.

According to the U.S. Food and Drug Administration (FDA), CGM systems are Class II medical devices that must meet stringent accuracy and safety standards. The FDA has cleared multiple generations of sensors and transmitters, each improving on the last in terms of wear time, calibration requirements, and data reliability.

The Core Components of a CGM System

A modern CGM system consists of three primary hardware and software components: the sensor, the transmitter, and the display device (most often a mobile app). Each component plays a distinct role in capturing, relaying, and presenting glucose data. Understanding how these parts work together helps users make informed choices about which system best fits their needs.

The Sensor: Measuring Glucose in Interstitial Fluid

The sensor is the heart of any CGM system. It is a small, flexible filament inserted just under the skin, typically in the abdomen, upper arm, or thigh. The sensor measures glucose levels in the interstitial fluid—the fluid that surrounds the cells—rather than directly in the bloodstream. There is a physiological lag of about 5 to 10 minutes between blood glucose changes and interstitial fluid glucose readings, but for most users this delay is clinically acceptable and well characterized.

Key features of modern sensors include:

  • Insertion mechanism: Most sensors are inserted with a spring-loaded applicator that makes the process quick and nearly painless. The inserter contains a thin needle (often less than 0.4 mm) that guides the sensor filament into the subcutaneous tissue and then retracts.
  • Wear duration: Sensors can be worn for 7 to 14 days depending on the brand, with some experimental models lasting up to 90 days. The wear time is limited by enzyme degradation, biofouling, and the body’s immune response to the foreign material.
  • Calibration needs: Some sensors are factory-calibrated and do not require any fingerstick checks after insertion. Others require one or two calibration readings per day to ensure accuracy. Factory-calibrated systems rely on advanced manufacturing controls and are generally preferred for convenience.
  • Accuracy metrics: Accuracy is reported using Mean Absolute Relative Difference (MARD). A MARD below 10% is considered excellent. Current-generation sensors from market leaders such as Dexcom and Abbott typically have MARD values between 8% and 9.5%.

The sensor contains an enzyme electrode that reacts with glucose to produce an electrical current proportional to the glucose concentration. This current is measured repeatedly—often every 5 minutes—and converted into a glucose reading in mg/dL or mmol/L.

The Transmitter: Reliable Wireless Data Relay

The transmitter is a small electronic module that snaps onto the sensor’s baseplate and handles all wireless communication. It contains a battery, a microprocessor, and a radio transmitter (typically Bluetooth Low Energy, or BLE). The transmitter collects raw data from the sensor, processes it into calibrated glucose values, and broadcasts those values to a paired receiver—usually a smartphone app or a dedicated handheld device.

Important aspects of transmitters include:

  • Battery life: Most transmitters have a rechargeable or disposable battery that lasts from 90 days to 12 months. Rechargeable transmitters (e.g., Dexcom G6) require periodic charging, while disposable ones (e.g., Abbott FreeStyle Libre) are discarded after the sensor session ends.
  • Wireless range: Bluetooth-based transmitters typically operate within a 10–20 meter range. Some older systems use radio frequency (RF) which can extend range but requires a dedicated receiver.
  • Data buffering: Transmitters often store up to several hours of data locally so that if the phone is out of range, readings are not lost. When the connection is restored, the app backfills the gap.
  • Firmware updates: Many modern transmitters can receive over-the-air firmware updates, allowing manufacturers to improve performance and add features without requiring hardware replacement.

The Mobile App and Display Devices

While early CGM systems required a dedicated receiver (a small handheld device), most users today rely on a mobile app installed on their smartphone. The app serves as the primary interface for viewing glucose data, setting alerts, and sharing reports with caregivers or healthcare providers. Dedicated receivers are still available for users who prefer a simpler device or who do not carry a smartphone.

Core app features include:

  • Real-time display: A trend graph shows current glucose, the direction and rate of change, and a history of recent readings. Colour-coded zones (e.g., green for in-range, red for high or low) make interpretation immediate.
  • Customizable alerts: Users can set thresholds for high and low glucose, as well as rate-of-change alerts that warn when glucose is dropping or rising rapidly. Predictive alerts can sound before a threshold is crossed.
  • Data logging and integration: Most apps allow manual entry of meals, insulin doses, and exercise. Some integrate with insulin pumps, electronic health records, and fitness platforms such as Apple Health or Google Fit.
  • Remote monitoring: The ability to share data with family members or clinicians via a follow app or cloud service is a critically important feature, especially for parents of children with diabetes and for older adults living alone.
  • Reporting and analytics: Standard reports include Time in Range (TIR), average glucose, standard deviation, and hypoglycemia patterns. These reports help guide therapy adjustments during clinic visits.

Leading mobile apps include Dexcom CLARITY, Abbott LibreLink, and Medtronic CareLink. Each offers slightly different analytics, but all aim to make the data actionable.

How CGM Systems Work Together

The three components form an integrated system. The sensor continuously measures glucose, the transmitter sends that data wirelessly to the app, and the app presents it to the user. Behind the scenes, the sensor measures a current every few seconds; the transmitter averages those readings and sends a new glucose value every 5 minutes. The app applies any calibration adjustments and displays the result.

Most CGM systems perform automatic recalibration using the sensor’s internal reference signals. For systems that require manual calibration, the app prompts the user to enter a fingerstick reading at specific times (e.g., after insertion and then once or twice daily). Calibration updates the algorithm’s offset and slope, improving accuracy over the life of the sensor.

Data security is handled through encryption (typically AES-128 or AES-256) over the Bluetooth link, and cloud platforms use HIPAA-compliant protocols for storage and transmission. Users should ensure their app and transmitter firmware are kept up to date to benefit from the latest security patches.

Clinical Benefits and Real-World Impact

The adoption of CGM technology has been driven by strong evidence of improved outcomes. A landmark study by the DIAMOND study group showed that adults with type 1 diabetes who used CGM had significant reductions in HbA1c and spent more time in target range compared to those using blood glucose monitoring alone. Similar benefits have been seen in type 2 diabetes populations.

Key clinical advantages include:

  • Lowered hypoglycemia risk: Real-time alerts for impending low glucose allow users to intervene before symptoms occur, drastically reducing severe hypoglycemic events.
  • Improved Time in Range: TIR (glucose 70–180 mg/dL) is now widely accepted as a surrogate endpoint. CGM users consistently achieve higher TIR, often exceeding 70% in well-controlled cohorts.
  • Reduced glycemic variability: Continuous data helps identify patterns that lead to swings, such as delayed insulin action or post-meal hyperglycemia, enabling proactive adjustments.
  • Better quality of life: The reduction in fingerstick burden and the peace of mind from knowing glucose levels at all times significantly improves psychological well-being and treatment satisfaction.

Limitations and Challenges

Despite its advantages, CGM technology is not without limitations. Understanding these helps users set realistic expectations and identify strategies to mitigate problems.

  • Cost and insurance coverage: CGM systems are expensive, particularly when purchased out of pocket. While coverage has expanded under Medicare and many private insurers, copays and deductibles can still be prohibitive for some patients. The cost of sensors (often $35–$70 per sensor) and transmitters (replacing every 3–12 months) adds up over time.
  • Accuracy in extreme conditions: CGM readings can be less accurate during rapid glucose changes (e.g., after eating or during exercise), at very low glucose levels, or when the sensor is affected by pressure (compression artifact). Most systems flag readings that may be unreliable and recommend a fingerstick check.
  • Skin irritation and adhesion issues: The adhesive patches used to secure sensors can cause contact dermatitis or allergic reactions in some people. The sensor filament itself can cause local inflammation or bruising. Rotating sites and using barrier wipes can help.
  • Calibration inconvenience: Even factory-calibrated systems advise users to verify with a fingerstick if symptoms do not match the reading. Self-calibration systems add a burden that some users find annoying, especially late at night or during illness.
  • Data overload: The wealth of information can be overwhelming. Without proper guidance, users may overreact to every upward trend or become anxious about minor fluctuations. Education and good app design are essential to keep data actionable without causing stress.

Additionally, CGM data is not yet accepted for all clinical decisions. For example, many healthcare providers still recommend confirming a hypoglycemia reading with a fingerstick before treating, especially if the CGM value seems inconsistent with symptoms.

The Future: Next-Generation Advances

The pace of innovation in CGM technology shows no signs of slowing. Several trends are shaping the next generation of devices:

Fully Implantable Sensors

Companies such as Senseonics have developed fully implantable CGM sensors that last up to 180 days and are placed under the skin in a brief procedure. These eliminate the need for frequent sensor changes and reduce the risk of adhesive allergy. The implant communicates with a smart transmitter worn as a patch or a wristband. The Eversense E3 system is one example that has received FDA approval.

Closed-Loop Systems

Integration with insulin pumps to create an artificial pancreas, or hybrid closed-loop system, is the most transformative application of CGM technology. Automated insulin delivery (AID) systems use CGM data to adjust basal insulin rates and deliver correction boluses automatically. Products like the Medtronic MiniMed 780G and the Tandem t:slim X2 with Control-IQ are already available, and newer systems are beginning to integrate glucagon as well.

Artificial Intelligence and Predictive Analytics

Machine learning models are being used to predict glucose levels 30–60 minutes ahead, allowing users to take preventive action. Some apps already provide these predictions, and future versions may incorporate real-time pattern recognition that suggests personalized meal bolus ratios and exercise adjustments.

Multi-Marker Sensors

Researchers are developing sensors that can measure not only glucose but also ketones, lactate, and other metabolites. A single sensor that can warn of diabetic ketoacidosis or exercise-induced lactate spikes would provide a more complete picture of metabolic health.

Choosing a CGM System: Key Considerations

Selecting the right CGM system depends on individual needs, lifestyle, and healthcare provider recommendations. Key factors to evaluate include:

  • Accuracy and MARD: Lower MARD generally means tighter agreement with blood glucose meters. Compare published MARD values for the sensor models you are considering.
  • Wear time and replacement frequency: Longer wear sensors (14+ days) reduce the hassle of frequent changes. Implantable sensors offer the longest intervals but require a provider insertion.
  • Calibration requirements: Factory-calibrated systems are more convenient but may have slightly higher MARD in the first 24 hours. Self-calibration systems may offer better accuracy for some users.
  • App ecosystem and sharing: Ensure the app is compatible with your smartphone model and operating system. Review the remote monitoring features if you need to share data with family or clinicians.
  • Cost and insurance: Check your insurance formulary and any pharmacy benefit restrictions. Some plans prefer one brand over another, which can significantly affect out-of-pocket costs.
  • Integration with insulin pumps: If you use or plan to use an AID system, compatibility between CGM and pump is essential. Most closed-loop systems require specific CGM models.

Consulting with a diabetes educator or endocrinologist can help clarify which system aligns with your daily routine and treatment goals. Many manufacturers also offer free trial sensors or patient assistance programs for those who qualify.

Conclusion

CGM technology has fundamentally changed the landscape of diabetes management by providing continuous, real-time insight into glucose trends. The interplay of a sensitive subcutaneous sensor, a reliable wireless transmitter, and a feature-rich mobile app creates a powerful tool that empowers users to take control of their health. While cost, accuracy limitations, and the need for occasional verification remain challenges, ongoing advances in sensor design, closed-loop integration, and data analytics promise to make CGM even more accessible and effective in the years ahead. Understanding each component and how they communicate is the first step toward leveraging the full potential of this life-changing technology.

For more detailed specifications and clinical guidelines, refer to the Dexcom G6 Product Page and Abbott's LibreView platform.